



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

September 8, 2020: 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**

- **Medical Director Update** **6:45 - 6:50**

- **Follow-up Items from Previous Meetings** **6:50 - 6:50**
 - None at this time

- **RetroDUR/ProDUR** **6:50- 7:10**
 - Introduce: Discussion Topics for 2021 RetroDUR Initiatives
 - Data presentation: PrEP therapy to Prevent HIV in at-risk populations

- **Clinical Update: Drug Reviews** **7:10-7:45**
(Public comment prior to Board action)

Biosimilar Drug Reviews

- None at this time.

Full New Drug Reviews

(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)

- Caplyta® (lumateperone)
 - Esperoct® (antihemophilic factor (recombinant), glycopegylated-exei)
 - Jatenzo® (testosterone undecanoate)
 - Secuado® (asenapine)
 - Talicia® (omeprazole magnesium, amoxicillin and rifabutin)
 - Xepi Cream® (ozenoxacin cream)
 - Zerviate Drops® (cetirizine)
-
- **New Managed Therapeutic Drug Classes** **7:45 -7:45**
 - None at this time

(Public comment prior to Board action)

- None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:45 - 8:25**
(Public comment prior to Board action)
 - Allergen Immunotherapy (New Drug Review Palforzia (arachis hypogaea) will be included)
 - Cytokine and CAM antagonists (changes effective 1/1/21), includes the following PDL classes:
 - Ankylosing Spondylitis
 - Gastrointestinal: Inflammatory Disease Biologics
 - Interleukin-1 Receptor Blockers
 - Psoriasis
 - Rheumatoid, Juvenile, & Psoriatic Arthritis
 - Iron Chelating Agents
 - NSAIDs (New Drug Review Relafen DS (nabumetone) will be included)
 - Opiate Dependence and Overdose Treatments
 - Otic Antibiotics
 - Phosphate Binders
 - Topical Analgesics
 - UC and Crohn’s Agents (Oral & Rectal)

- **Review of Newly Developed/Revised Criteria** **8:25 - 8:30**
(Public comment prior to Board action)
 - 2020/21 Influenza Vaccine

- **General Announcements** **8:30 – 8:30**

- **Adjourn** **8:30**